2cureX

2cureX Net Debt / EBITDA

Delisted·Sep 2, 2026

The Net Debt to EBITDA of 2cureX (2CUREX.ST) as of Oct 29, 2026 is 1.08. In the previous year, Net Debt to EBITDA was 0.37 — a change of 191.43% (higher).

Net Debt / EBITDA

1.08

YoY

191.43%

Last updated:

Net Debt to EBITDA of 2cureX is 2024 1.08 . Net Debt to EBITDA of 2cureX was 2023 0.37 . It decreases by 191.43% higher compared to the previous year.

The 2cureX Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
5.43 SEK
Jan 1, 2018
2.51 SEK
Jan 1, 2019
4.06 SEK
Jan 1, 2020
2.61 SEK
Jan 1, 2021
2.44 SEK
Jan 1, 2022
1.41 SEK
Jan 1, 2023
0.37 SEK
Jan 1, 2024
1.08 SEK
The 2cureX Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
1.08+191.43%
0.37-73.65%
1.41-42.29%
2.44-6.42%
2.61-35.60%
4.06+61.84%
2.51-53.81%
5.43-27.82%
7.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

2cureX Stock analysis

What does 2cureX do? 2cureX AB develops anti-cancer treatments through research and development, focusing on diagnostic substances to optimize cancer patient care. Its key product, IndiTreat - CRC, enables healthcare professionals to test chemotherapies and experimental treatments using three-dimensional micro tumors created from patient tumor samples. The company also offers IndiTreat - OVA for ovarian cancer and IndiTreat - KDN for kidney cancer, forming its product pipeline. 2cureX AB operates through 2cureX A/S, targeting healthcare providers and oncology specialists who seek personalized treatment solutions for cancer patients. The company generates revenue by providing diagnostic services and product candidates to healthcare institutions. IndiTreat - CRC, IndiTreat - OVA, and IndiTreat - KDN are sold as diagnostic tools to hospitals and clinics specializing in cancer treatment. These products help medical teams select the most effective therapies for individual patients, reducing trial-and-error in cancer care. 2cureX AB's business model relies on the adoption of its diagnostic platform by oncology departments seeking precision medicine approaches. 2cureX AB's primary customers are healthcare professionals and institutions involved in cancer treatment, particularly those focused on colorectal, ovarian, and kidney cancers. The firm's diagnostic solutions are used to guide treatment decisions, with IndiTreat - CRC being the most advanced product in its pipeline. By offering tailored diagnostic services, 2cureX AB supports healthcare providers in delivering targeted therapies, aligning with the growing demand for personalized cancer care strategies. 2cureX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2cureX stock

Net Debt to EBITDA of 2cureX is 1.08 in 2024.

Net Debt to EBITDA of 2cureX changed from 0.37 to 1.08, representing a 191.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA 2cureX since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's 2cureX with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — 2cureX

All Key Metrics — 2cureX